The mixed human umbilical cord blood-derived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro

References

• Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, et al. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori 2007; 93: 248–56.
   PubMed Web of Science ®Google Scholar
• Kang SG, Kim JH, Nam DH, Park K. Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol Med Chir 2005; 45: 232–8.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 2005; 352: 987–96.
   PubMed Web of Science ®Google Scholar
• Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neuro-oncol 2007; 83: 53–60.
   PubMed Web of Science ®Google Scholar
• Kang SG, Kim JS, Park K, Kim JS, Groves MD, Nam DH. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 2006; 15: 7–13.
   PubMed Web of Science ®Google Scholar
• Scheda A, Finjap JK, Tuettenberg J, Brockmann MA, Hochhaus A, Hofheinz R, et al. Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. Tumori 2007; 93: 31–6.
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang YF, Peng B, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12: 4899-907.
   Google Scholar
• Brower V. Search and destroy: recent research exploits adult stem cells' attraction to cancer. J Natl Cancer Inst 2005; 97: 414–6.
   PubMed Web of Science ®Google Scholar
• Barry FP. Biology and clinical applications of mesenchymal stem cells. Birth Defects Res C Embryo Today 2003; 69: 250–6.
   PubMedGoogle Scholar
• Short B, Brouard N, Occhiodoro-Scott T, Ramakrishnan A, Simmons PJ. Mesenchymal stem cells. Arch Med Res 2003; 34: 565–71.
   PubMed Web of Science ®Google Scholar
• Kang SG, Ryu CH, Jeun SS, Park CK, Shin HJ, Kim JH, etal. Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood. Childs Nerv Syst 2004; 20: 154–62.
   PubMed Web of Science ®Google Scholar
• Kang SG, Jeun SS, Lim JY, Kim SM, Yang YS, Oh WI, et al. Cytotoxicity of human umbilical cord blood-derived mesench-ymal stem cells against human malignant glioma cells. Childs Nerv Syst 2008; 24: 293–302.
   PubMed Web of Science ®Google Scholar
• Ray SK, Patel SJ, Welsh CT, Wilford GG, Hogan EL, Banik NL. Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. J Neurosci Res 2002; 69: 197–206.
   PubMed Web of Science ®Google Scholar
• Shinoura N, Muramatsu Y, Yoshida Y, Asai A, Kirino T, Hamada H. Adenovirus-mediated transfer of caspase-3 with Fas ligand induces drastic apoptosis in U-373MG glioma cells. Exp Cell Res 2000; 256: 423–33.
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756–60.
   PubMed Web of Science ®Google Scholar
• Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133 +cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Mule JJ. New approaches to the immunotherapy of cancer. Ann Intern Med 1988; 108: 853–64.
   PubMed Web of Science ®Google Scholar
• Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenburg SA. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity and histologic findings. J Am Med Assoc 1986; 256: 3117-24.
   Google Scholar
• Pizza G, Viza D, De Vinci C, Paschuchi JM, Busutti L, Bergami T. Intralymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study. Cytokine Res 1988; 7: 45–8.
   Google Scholar
• Sama G, Collins J, Figlin R, Robertson P, Altrock B, Abels R. A pilot study of intralymphatic interleukin-2: II. Clinical and biological effects. J Biol Response Modif 1990; 9: 81–6.
   PubMedGoogle Scholar
• Gandolfi L, Solmi L, Pizza GC, Bertoni F, Muratori R, De Vinci C, et al. Intratumoral echo-guided injection of interleukin-2 and lymphokine-activated killer cells in hepato-cellular carcinoma. Hepatogastroenterology 1989; 36: 352–6.
   PubMed Web of Science ®Google Scholar
• Grivnik K, Anderson J. The role of T cell growth stimulating factors in T cell triggering. Immunol Rev 1980; 51: 35–59.
   PubMed Web of Science ®Google Scholar
• Ralph P, Nakoinz I, Rennick D. Role of interleukin 2, interleukin 4, and alpha, beta and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activ-ity. J Exp Med 1988; 167: 712–7.
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Chen W-F, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989; 143: 1210–4.
   PubMed Web of Science ®Google Scholar
• Wallach D, Fellous M, Revel M. Preferential effect of interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 1982; 299: 833–6.
   PubMed Web of Science ®Google Scholar
• Carrel S, Schmidt-Kessen A, Giuffre L. Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expres-sion of HLA-ABC and tumor-associated antigens. Eur J Immunol 1985; 15: 118–23.
   PubMed Web of Science ®Google Scholar
• Gross N, Beck D, Favre S, Carrel S. In vitro antigenic modulation of human neuroblastoma cells induced by IFN-gamma, retinoic acid and dibutyryl cyclic AMP. Int J Cancer 1987; 39: 521–9.
   PubMed Web of Science ®Google Scholar
• Maheshwari RK, Srikantan V, Bhartiya D, Kleinman HK, Grant DS. Differential effects of interferon gamma and alpha on in vitro model of angiogenesis. J Cell Physiol 1991; 146: 164–9.
   PubMed Web of Science ®Google Scholar
• Yang SE, Ha CW, Jung M, Jin HJ, Lee M, Song H, et al. Mesenchymal stem/progenitor cells developed in cultures from UC blood. Cytotherapy 2004; 6: 476–86.
   PubMed Web of Science ®Google Scholar
• Kang SG, Jeun SS, Lim JY, Yoo DS, Huh PW, Cho KS, et al. Cytotoxicity of rat marrow stromal cells against malignant glioma cells. Childs Nerv Syst 2005; 21: 528–38.
   PubMed Web of Science ®Google Scholar
• Birnbaum T, Roider J, Schankin CJ, Padovan CS, Schichor C, Goldbrunner R, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 2007; 83: 241–7.
   PubMed Web of Science ®Google Scholar
• Miletic H, Fischer Y, Litwak S, Giroglou T, Waerzeggers Y, Winkeler A, et al. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expres-sing a suicide gene. Mol Ther 2007; 15: 1373–81.
   PubMed Web of Science ®Google Scholar
• Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307–18.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004; 11: 1155–64.
   PubMed Web of Science ®Google Scholar
• Schichor C, Birnbaum T, Etminan N, Schnell O, Grau S, Miebach S, et al. Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol 2006; 199: 301–10.
   PubMed Web of Science ®Google Scholar
• Pisati F, Belicchi M, Acerbi F, Marchesi C, Giussani C, Gavina M, et al. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models. Cancer Res 2007; 67: 3054–63.
   PubMed Web of Science ®Google Scholar
• Solves P, Moraga R, Saucedo E, Perales A, Soler MA, Larrea L, et al. Comparison between two strategies for umbilical cord blood collection. Bone Marrow Transplant 2003; 31: 269–73.
   PubMed Web of Science ®Google Scholar
• Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, et al. Substrate specificities of caspase family proteases. J Biol Chem 1997; 272: 9677–82.
   PubMed Web of Science ®Google Scholar
• Stennicke HR, Renatus M, Meldal M, Salvesen GS. Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8. Biochem J 2000; 350: 563–8.
   PubMed Web of Science ®Google Scholar
• Stennicke HR, Ryan CA, Salvesen GS. Reprieval from execution: the molecular basis of caspase inhibition. Trends Biochem Sci 2002; 27: 94–101.
   PubMed Web of Science ®Google Scholar
• Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22: 8543–67.
   PubMed Web of Science ®Google Scholar
• Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326: 1–16.
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandenabeele P. Caspases in cell survival, proliferation and differentiation. Cell Death Differ 2007; 14: 44–55.
   PubMed Web of Science ®Google Scholar
• Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007–8.
   PubMed Web of Science ®Google Scholar
• Bhagwati SN. Treatment of glioma with intratumoral instilla-tion of autologous lymphocytes. Childs Nerv Syst 1989; 5: 38–40.
   PubMed Web of Science ®Google Scholar
• Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76: 840–52.
   PubMed Web of Science ®Google Scholar
• Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol 2001; 39: 31–42.
   PubMed Web of Science ®Google Scholar
• Huang Y, Hayes RL, Wertheim S, Arbit E, Scheff R. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report. Crit Rev Oncol Hematol 2001; 39: 17–23.
   PubMed Web of Science ®Google Scholar
• Jacobs SK, Parham CW, Holcomb B, Ikejiri B, Kornblith PL, Grimm EA. Lymphokine activated killer (LAK) cell mediated killing of human glioma: effect of pretreating glioma with various membrane modifying agents. J Neurooncol 1987; 5: 5–10.
   PubMed Web of Science ®Google Scholar
• Kruse CA, Mitchell DH, Lillehei KO, Johnson SD, McCleary EL, Moore GE, et al. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro. Cancer 1989; 64: 1629–37.
   Google Scholar
• Merchant RE, Ellison MD, Young HF. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations. J Neurooncol 1990; 8: 173–88.
   PubMed Web of Science ®Google Scholar